B7H3 靶向抗体药物偶联物治疗晚期实体瘤：1/1b期试验

文章预览

SCI 30 March 2025 A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial  (Nat Med, IF: 58.7) Ma Y, Yang Y, Huang Y, et al: A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med 10.1038/s41591-025-03600–2, 2025 Abstract  摘要 Antibody-drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker. Here we report the findings from a large-scale, global, multicenter, phase 1 trial evaluating the safety, pharmacokinetics and preliminary efficacy of YL201 in patients with advanced solid tumors refractory to standard therapies. The trial included a dose-escalation part (phase 1) and a dose-expansion part (phase 1b). A total of 312 patients were enrolled across multiple tumor types, including extens ………………………………